Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy - PubMed (original) (raw)
. 2015 Jun;30(6):1009-14.
doi: 10.1111/jgh.12897.
Keigo Kawashima, Masato Yoneda, Satoru Saito, Yuji Ogawa, Yasushi Honda, Takaomi Kessoku, Kento Imajo, Hironori Mawatari, Koji Fujita, Satoru Saito, Yoshio Hirayasu, Atsushi Nakajima
Affiliations
- PMID: 25619308
- DOI: 10.1111/jgh.12897
Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy
Wataru Tomeno et al. J Gastroenterol Hepatol. 2015 Jun.
Abstract
Background and aim: Major depressive disorder (MDD) is an important public health problem, and it is often comorbid with many chronic diseases. The purpose of this study was to identify the clinical features of non-alcoholic fatty liver disease (NAFLD) patients comorbid with MDD and to investigate the influence of MDD on the effect of treatment in patients with NAFLD.
Methods: A total of 258 patients with biopsy-proven NAFLD were included. MDD was diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. The patients were followed up for 48 weeks under standard care for NAFLD, which consisted mainly of lifestyle modification.
Results: There were 32 patients comorbid with MDD. They were characterized by more severe histological steatosis and higher NAFLD activity score, and also significantly higher levels of serum aminotransferase, γ-glutamyl transpeptidase and ferritin, than age-and-sex-matched NAFLD patients without MDD. Moreover, NAFLD patients with MDD showed poor response to the standard care for NAFLD, in body weight loss and in other parameters. Particularly, NAFLD patients with unstable MDD (not in full/partial remission) showed severe resistance to the treatment.
Conclusion: This is the first study to demonstrate the clinical features and response to therapy of NAFLD patients comorbid with MDD. The comorbid state of MDD was associated with more severe histological liver steatosis and worse treatment outcomes in patients with NAFLD. Further investigations are required to develop new lifestyle modification programs that enable NAFLD patients with MDD to achieve the treatment goal.
Keywords: major depressive disorder; non-alcoholic fatty liver disease; steatohepatitis.
© 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
Similar articles
- Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
Pallayova M, Taheri S. Pallayova M, et al. Clin Obes. 2014 Oct;4(5):243-53. doi: 10.1111/cob.12068. Epub 2014 Jul 28. Clin Obes. 2014. PMID: 25825857 Review. - Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.
Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Gelli C, et al. World J Gastroenterol. 2017 May 7;23(17):3150-3162. doi: 10.3748/wjg.v23.i17.3150. World J Gastroenterol. 2017. PMID: 28533672 Free PMC article. Clinical Trial. - Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
Kim H, Lee K, Lee KW, Yi NJ, Lee HW, Hong G, Choi Y, You T, Suh SW, Jang JJ, Suh KS. Kim H, et al. Clin Transplant. 2014 May;28(5):521-9. doi: 10.1111/ctr.12343. Epub 2014 Apr 16. Clin Transplant. 2014. PMID: 24579874 - Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
Chan WK, Ida NH, Cheah PL, Goh KL. Chan WK, et al. J Dig Dis. 2014 Oct;15(10):545-52. doi: 10.1111/1751-2980.12175. J Dig Dis. 2014. PMID: 25060399 - Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Federico A, et al. World J Gastroenterol. 2014 Dec 7;20(45):16841-57. doi: 10.3748/wjg.v20.i45.16841. World J Gastroenterol. 2014. PMID: 25492998 Free PMC article. Review.
Cited by
- Development and validation of a predictive nomogram for the risk of MAFLD in postmenopausal women.
Yang M, Chen X, Shen Q, Xiong Z, Liu T, Leng Y, Jiao Y. Yang M, et al. Front Endocrinol (Lausanne). 2024 Aug 6;15:1334924. doi: 10.3389/fendo.2024.1334924. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39165508 Free PMC article. - Association of MTTP gene variants with pediatric NAFLD: A candidate-gene-based analysis of single nucleotide variations in obese children.
Dai D, Wen F, Zhou S, Su Z, Liu G, Wang M, Zhou J, He F. Dai D, et al. PLoS One. 2017 Sep 27;12(9):e0185396. doi: 10.1371/journal.pone.0185396. eCollection 2017. PLoS One. 2017. PMID: 28953935 Free PMC article. - Interrelationship between physical activity and depression in nonalcoholic fatty liver disease.
Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM. Weinstein AA, et al. World J Hepatol. 2022 Mar 27;14(3):612-622. doi: 10.4254/wjh.v14.i3.612. World J Hepatol. 2022. PMID: 35582293 Free PMC article. - Non-alcoholic Fatty Liver Disease and Depression: Evidence for Genotype × Environment Interaction in Mexican Americans.
Manusov EG, Diego VP, Sheikh K, Laston S, Blangero J, Williams-Blangero S. Manusov EG, et al. Front Psychiatry. 2022 Jul 1;13:936052. doi: 10.3389/fpsyt.2022.936052. eCollection 2022. Front Psychiatry. 2022. PMID: 35845438 Free PMC article. - Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention.
Tobaruela-Resola AL, Riezu-Boj JI, Milagro FI, Mogna-Pelaez P, Herrero JI, Elorz M, Benito-Boillos A, Tur JA, Martínez JA, Abete I, Zulet MA. Tobaruela-Resola AL, et al. Nutrients. 2024 May 21;16(11):1547. doi: 10.3390/nu16111547. Nutrients. 2024. PMID: 38892481 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical